1. Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD. (2nd August 2016) Authors: Usmani, Saad; Ahmadi, Tahamtan; Ng, Yvette; Lam, Annette; Desai, Avinash; Potluri, Ravi; Mehra, Maneesha Journal: Oncologist Issue: Volume 21:Number 11(2016) Page Start: 1355 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Analysis of Real‐World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD. (2nd August 2016) Authors: Usmani, Saad; Ahmadi, Tahamtan; Ng, Yvette; Lam, Annette; Desai, Avinash; Potluri, Ravi; Mehra, Maneesha Journal: Oncologist Issue: Volume 21:Number 11(2016) Page Start: 1355 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Treatment evolution for metastatic castration‐resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real‐world data. (29th December 2015) Authors: Flaig, Thomas W.; Potluri, Ravi C.; Ng, Yvette; Todd, Mary B.; Mehra, Maneesha Journal: Cancer medicine Issue: Volume 5:Number 2(2016:Feb.) Page Start: 182 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗